Chemical Property of Bumetanide
Chemical Property:
- Appearance/Colour:crystalline solid
- Vapor Pressure:6.89E-14mmHg at 25°C
- Melting Point:230-231 °C
- Refractive Index:1.612
- Boiling Point:571.2 °C at 760 mmHg
- PKA:pK1 3.6, pK2 7.7(at 25℃)
- Flash Point:299.3 °C
- PSA：127.10000
- Density:1.347 g/cm3
- LogP:4.89060
- Storage Temp.:Store at RT
- Solubility.:Practically insoluble in water, soluble in acetone and in alcohol, slightly soluble in methylene chloride. It dissolves in dilute solutions of alkali hydroxides.
- Water Solubility.:Soluble in ethanol (10 mg/ml), DMSO (25 mg/ml), acetone, benzene, methanol, propylene glycol, and water (<1 mg/ml).
- XLogP3:2.8
- Hydrogen Bond Donor Count:3
- Hydrogen Bond Acceptor Count:7
- Rotatable Bond Count:8
- Exact Mass:364.10929292
- Heavy Atom Count:25
- Complexity:528
- Purity/Quality:
-
98% *data from raw suppliers
Bumetanide *data from reagent suppliers
Safty Information:
- Pictogram(s):
- Hazard Codes:
- MSDS Files:
-
SDS file from LookChem
Total 1 MSDS from other Authors
Useful:
- Canonical SMILES:CCCCNC1=C(C(=CC(=C1)C(=O)O)S(=O)(=O)N)OC2=CC=CC=C2
- Recent ClinicalTrials:Mechanisms of Diuretic Resistance in Heart Failure, Aim 1
- Recent EU Clinical Trials:Diuretic Treatment in Acute Heart Failure with Volume Overload Guided by Serial Spot Urine Sodium Assessment
-
Uses
antineoplastic, alkylating agent Bumetanide is used for relieving edema associated with cardiac insufficiency, for liver and
kidney diseases including nephrotic syndrome, for ascites, and hypertension.
-
Therapeutic Function
Diuretic
-
Clinical Use
A diuretic structurally related to furosemide is bumetanide. Bumetanide also functions as a high-ceiling diuretic in the ascending limb of the loop of Henle. It has a
duration of action of approximately 4 hours. The uses of Bumetanide are similar to those described for furosemide. The dose of bumetanide is 0.5 to 2 mg/day given as
a single dose.
-
Drug interactions
Potentially hazardous interactions with other drugs
Analgesics: increased risk of nephrotoxicity with
NSAIDs; antagonism of diuretic effect with
NSAIDs. Anti-arrhythmics: risk of cardiac toxicity with
anti-arrhythmics if hypokalaemia occurs; effects of
lidocaine and mexiletine antagonised.
Antibacterials: increased risk of ototoxicity with
aminoglycosides, polymyxins and vancomycin; avoid
with lymecycline.
Antidepressants: increased risk of hypokalaemia
with reboxetine; enhanced hypotensive effect with
MAOIs; increased risk of postural hypotension with
tricyclics.
Antiepileptics: increased risk of hyponatraemia with
carbamazepine.
Antifungals: increased risk of hypokalaemia with
amphotericin.
Antihypertensives: enhanced hypotensive effect;
increased risk of first dose hypotensive effect
with alpha-blockers; increased risk of ventricular
arrhythmias with sotalol if hypokalaemia occurs.
Antipsychotics: increased risk of ventricular
arrhythmias with amisulpride or pimozide if
hypokalaemia occurs - avoid with pimozide;
enhanced hypotensive effect with phenothiazines.
Atomoxetine: increased risk of ventricular
arrhythmias if hypokalaemia occurs.
Cardiac glycosides: increased toxicity if hypokalaemia
occurs.
Cytotoxics: increased risk of ventricular arrhythmias
due to hypokalaemia with arsenic trioxide; increased
risk of nephrotoxicity and ototoxicity with platinum
compounds.
Lithium: risk of toxicity.
